Transaction DateRecipientSharesTypePriceValue
1st January 2021James F Young10,000Exercise of derivative$0.00
31st December 2020James F Young1,000Exercise of derivative$50.00$50,000.00
31st December 2020James F Young9,000Open or private sale$112.98$1,016,824.50
31st December 2020James F Young2,000Open or private sale$113.60$227,190.00
31st December 2020Richard Douglas1,000Exercise of derivative$50.00$50,000.00
31st December 2020James F Young10,000Exercise of derivative$51.40$514,000.00
28th December 2020Rachel K. King84,176Open or private sale$3.91$329,128.16
28th December 2020Rachel K. King130,821Exercise of derivative$1.12$146,519.52
16th December 2020Michael A Jr Mcmanus615Grant/award etc.$25.19$15,491.85
1st October 2020Stanley C Erck2Open or private sale$108.57$217.13
Novavax
Novavax logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.


Novavax, Inc. is a late-stage biotechnology company. It focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. Its vaccine candidates include ResVax and NanoFlu.


Ticker: NVAX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1000694
Employees: 379
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $424 M (0%)
Assets, Current: $636 M (554%)
Property, Plant and Equipment, Net: $115 M (908%)
Other Assets, Noncurrent: $56 M (685%)
Assets: $932 M (438%)
Accounts Payable, Current: $9 M (217%)
Accrued Liabilities, Current: $39 M (160%)
Liabilities, Current: $213 M (727%)
Other Liabilities, Noncurrent: $11 M (6%)
Liabilities: $548 M (52%)
Common Stock, Value, Issued: $612 Th (88%)
Common Stock, Shares, Issued: $61 M (89%)
Retained Earnings (Accumulated Deficit): $1 B (4%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $13 M (5%)
Treasury Stock, Value: $26 Th (2%)
Treasury Stock, Shares: $514 Th (9%)
Stockholders' Equity (Parent): $185 M (0%)
Liabilities and Equity: $932 M (438%)
Research and Development: $35 M (-32%)
General and Administrative Expenses: $18 M (-34%)
Operating Income/Loss: $17 M (-57%)